Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ≥18 yrs old on the day of signing informed consent~* Diagnosed with Primary Insomnia~* Good physical and mental health~* Participant ≥65 yrs old score at least 25 on the Mini Mental State Examination~* A female participant who is of reproductive potential has a negative serum pregnancy test and agrees to use contraception~* Reports difficulty with initiating and maintaining sleep during the 4 weeks prior to Visit 1 (accordingly to specific protocol criteria)~* Reports spending 6.5 to 9 hours nightly in bed on at least 3 out of 7 nights prior to Visit 1~* Regular bedtime is between 9 pm-1 am~* Willing to refrain from napping while in study~* Able to read, understand and complete questionnaires and all diaries~* Willing to limit alcohol, caffeine, and nicotine consumption while in the study~* For a portion of participants: Must be willing to stay overnight in a sleep laboratory and must be willing to stay in bed for at least 8 hours each night while at the sleep laboratory~Exclusion Criteria:~* Female participant is pregnant and/or breastfeeding at Prestudy visit, or expecting to conceive while in study~* History or diagnosis of another sleep disorder~* Difficulty sleeping due to a medical condition~* History of a neurological disorder~* History of bipolar disorder, psychotic disorder, or posttraumatic stress disorder, or current psychiatric disorder that requires a prohibited medication~* Ongoing depression~* History of substance abuse or dependence~* History or current evidence of a clinically significant cardiovascular disorder or clinically significant electrocardiogram (ECG) at Prestudy Visit~* Taking certain prohibited medications~* Consumption of the equivalent of \>15 cigarettes a day~* History of malignancy ≤5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Participant is considered morbidly obese~* Previously randomized in another investigational study of suvorexant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suvorexant HD (Type: EXPERIMENTAL): Drug
- Suvorexant LD (Type: EXPERIMENTAL): Drug
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).